thymulin: Frequently Asked Questions
Indexed questions from peer-reviewed literature, public questions, and community research discussions. Every quantitative answer cites a source in the references index.
A nine-amino-acid (nonapeptide) hormone secreted by thymic epithelial cells, thymulin acts as a circulating immune signal for T-lymphocyte maturation and cytokine regulation. Its full scientific name is Facteur Thymique Serique (FTS). Molecular weight: 858.8 Da. Sequence: Glu-Ala-Lys-Ser-Gln-Gly-Gly-Ser-Asn. It requires zinc to function.[1][3]
In published research, thymulin is studied for T-lymphocyte maturation, immune modulation, anti-inflammatory cytokine balance, analgesic effects, and — in preclinical models — neuroprotection and hair follicle stimulation. It is not approved for human therapeutic use in any jurisdiction.[3][6][7][17]
thymulin is not an approved drug. It is an endogenous nonapeptide hormone produced by the thymus and, in synthetic form, a research compound. No Phase 2 or Phase 3 clinical trials of synthetic thymulin are registered on ClinicalTrials.gov. No FDA IND or NDA has been identified for the compound.[18]
thymulin is produced exclusively by the epithelial cells of the thymus — specifically the reticulo-epithelial cell population. Two distinct thymic epithelial cell subtypes secrete it under neuroendocrine regulation. No other organ is a physiological source. After thymectomy, circulating thymulin disappears.[3]
Thymulin titres peak in children aged 5–10 years (mean titre 4.77) and progressively fall from adolescence, reaching a nadir at age 36 (mean titre 0.66) that remains stable through the oldest subjects tested (age 80, mean 0.55 ± 0.16).[2] The age-related decline involves both thymic involution and reduced zinc saturation of circulating thymulin peptide.[5]
thymulin induces T-cell differentiation by promoting CD2, CD3, CD4, and CD8 surface-marker expression on thymocyte precursors.[3] It also enhances natural killer cell activity at low doses,[10] modulates cytokine production by suppressing IL-1β, IL-2, IL-6, TNF-α, and IFN-γ,[9] stimulates pituitary hormone release,[11] and attenuates inflammatory and neuropathic pain signaling via NF-κB and MAPK pathway inhibition.[6][13] All these effects require zinc.[1]
Thymuline is an alternate spelling of thymulin — the same compound. It promotes T-cell maturation and requires zinc for its active conformation. Loss of zinc binding renders the nonapeptide biologically inert; the zinc-bound form (Zn-FTS) is the active species measured in rosette inhibition assays and functional immune studies.[1][3]
Preclinical models report minimal adverse effects at studied concentrations.[9][13][17] Human safety data are limited; no IND or NDA for synthetic thymulin has been filed with the FDA, and no Phase 2 or Phase 3 trials exist. A noteworthy preclinical signal: low-dose thymulin enhanced NK cytotoxicity while high-dose thymulin suppressed it — a bidirectional dose-response relevant to immune research protocol design.[10]
Studies in rodent and ex-vivo models report: immune reconstitution via T-cell maturation, reduction of pro-inflammatory cytokines (IL-1β, IL-6, TNF-α), analgesic effects comparable to NSAID comparators in rodent pain models, neuroprotective effects in EAE autoimmune models, and — in a small open-label human pilot — 32% increase in vellus hairs and 23% increase in intermediate hairs with topical zinc-thymulin.[6][9][13][17]
thymulin is a single defined nine-amino-acid endogenous hormone (Glu-Ala-Lys-Ser-Gln-Gly-Gly-Ser-Asn) whose bioactivity requires zinc. Thymalin is a polypeptide complex extracted from bovine thymus glands, used primarily in Russian bioregulator research. The two are related by origin (both thymic) but distinct in composition: thymulin is a precisely defined nonapeptide; thymalin is a heterogeneous multi-peptide extract with less-characterized receptor pharmacology.[16]
Composition: thymulin is a single, sequenced nine-amino-acid peptide. Thymalin is a polypeptide mixture extracted from bovine thymus tissue. Mechanism: thymulin acts via defined T-cell receptor-mediated differentiation signaling requiring zinc. Thymalin’s effects are attributed to a mixture of thymic peptides with less-characterized pharmacology. Research base: thymulin has a cleaner mechanistic literature; thymalin has a longer Russian clinical history, including a 6-year mortality study.[16]
No. thymulin is a single defined nine-amino-acid endogenous hormone. Thymalin is a polypeptide complex extracted from bovine thymus glands used in Russian immunological research. They share a thymic origin but differ in composition, mechanism, research base, and regulatory history. Confusing the two is common in community discussions.[16]
Both are thymus-derived immune peptides. Thymosin alpha-1 (28 amino acids) targets innate and adaptive immunity broadly — it has approved status in some jurisdictions for hepatitis and cancer adjunct indications. thymulin (9 amino acids) acts more specifically on T-cell maturation and requires a zinc co-factor for activity. No co-administration studies were identified in peer-reviewed literature.
thymulin is a zinc-dependent nonapeptide focused on T-cell maturation and immune regulation. Thymosin beta-4 (TB-500) is a 43-amino-acid actin-sequestering peptide with primary studied roles in wound repair, tissue regeneration, and angiogenesis. Different mechanisms, different primary target tissues, and different studied use cases. Neither is FDA-approved for therapeutic use.
The range spans from picomolar concentrations (0.5–50 pM in vitro pituitary assays[11]) to milligram-per-kilogram doses (1.5 mg/kg IP in the nanoparticle EAE study[13]). In rodent pain models, the PAT analogue was used at 0.25–200 μg/rat IP. No validated human dosing protocol exists in the peer-reviewed literature.
A pilot open-label study (n=18, androgenetic alopecia, Norwood 2–7) associated topical zinc-thymulin with a 32% mean increase in vellus hairs and a 23% increase in intermediate hairs at 6 months.[17] The study lacks a placebo control and has a small sample size. It is the only published human efficacy signal for zinc-thymulin in hair. Controlled, blinded trials do not exist in the peer-reviewed record.
Preclinical and longevity research suggests thymalin and epitalon (epithalamin) may exert complementary effects on neuroendocrine regulation, with a 6-year mortality study reporting additive reduction in elderly patients.[16] No controlled human data on thymulin-epitalon effects on sleep architecture exist in peer-reviewed literature. Extrapolation from the thymalin mortality data to sleep effects of the synthetic thymulin nonapeptide is not supported by direct evidence.
Rodent studies examining multi-week thymulin protocols report immune parameter changes; however, no specific 30-day subcutaneous protocol was identified in the indexed peer-reviewed record. The most comparable rodent protocol is the 25-day every-other-day IP nanoparticle EAE study.[13] Extrapolation from rodent IP data to human subcutaneous outcomes is not supported by controlled trial data.
Preclinical studies use intraperitoneal injection most commonly in rodent models,[6][7][9][13] intravenous injection in swine studies,[14] and intramuscular for gene therapy vector delivery.[12] Subcutaneous administration appears in community protocols but comparative bioavailability data between IM and SC routes have not been characterized in any peer-reviewed pharmacokinetic study.
In the avian NK cell study, measurable NK cytotoxicity changes were recorded at 10 days post-infection in thymulin-treated birds.[10] In the PAT analgesic models, peak inhibition occurred 1–2 hours post-treatment.[7] In the EAE nanoparticle study, clinical score improvement was progressive over 25 days.[13] Timing is model- and dose-dependent; no human immune onset data exists.
Community observations vary widely in anecdotal reports. Controlled research endpoints (cytokine levels, T-cell ratios, NK cytotoxicity, clinical disease scores) differ substantially from subjective reports. The absence of randomized human clinical trials makes outcome prediction unreliable for any individual. Published human data are limited to the zinc-thymulin hair pilot (n=18, open-label)[17] and earlier zinc-deficiency studies.[4]
No peer-reviewed literature specifically characterizes epitalon + thymulin + amlexanox as a combination. Each compound has independent preclinical data; no overlapping pharmacokinetic, safety, or pharmacodynamic studies exist for this triple combination. The mechanistic profiles are distinct: thymulin (immune/T-cell), epitalon (pineal/anti-aging bioregulator), amlexanox (TBK1/IKK-epsilon inhibitor).
The Vickers (2017) pilot study used a water-based topical spray formulation synthesized via Fmoc solid-phase protocol, applied to the scalp over 4–10 months.[17] Specific vehicle composition, concentration, and application frequency are not fully detailed in the published study. No validated, standardized topical protocol exists in the peer-reviewed record.
Thymalin (bovine thymic polypeptide extract) was studied in severe COVID-19 in Russian clinical research — not the defined thymulin nonapeptide. thymulin itself has not been evaluated in post-COVID or vaccine-related immune conditions in published controlled trials. The compositional difference between thymalin and thymulin prevents direct extrapolation.